CTD Holdings President Named Chairman of 18th International Cyclodextrin Symposium
June 05 2014 - 8:00AM
Marketwired
CTD Holdings President Named Chairman of 18th International
Cyclodextrin Symposium
Dr. Jeffrey Tate Will Chair 2016 Event to Be Held in
Gainesville, Fla.
ALACHUA, FL--(Marketwired -
June 05, 2014) - CTD Holdings, Inc. (OTCQB: CTDH), a distributor and manufacturer of
cyclodextrin products including the orphan drug designated
Trappsol® Cyclo™, today announced that President and Director Dr.
Jeffrey Tate has been named Chairman of the 18th International
Cyclodextrin Symposium to be held in Gainesville, Fla. in 2016. The
Symposium Advisory Board reviewed three proposals to host the 2016
meeting and selected Dr. Tate's presentation based on the extensive
preparation that has already been done. "I am delighted that our
proposal was selected from a strong field," Dr. Tate said.
"Researchers and businesses in Gainesville played important roles
in the early days of cyclodextrin commercialization. Holding the
Symposium here recognizes those historical contributions and the
bright future of cyclodextrins being created by the CTD Holdings
Family of Companies. Our team looks forward to welcoming colleagues
from around the world."
The International Cyclodextrin Symposium is a global gathering
of academic and industry researchers to present and discuss the
latest developments in cyclodextrin research and applications.
Attendees are the opinion leaders in this rising field of interest;
they include biologists, chemists, material scientists and
engineers. The Symposium is held every two years with the venue
selected from proposals solicited by the Advisory Board.
The 18th International Cyclodextrin Symposium will be held at
the Hilton University of Florida Conference Center in Gainesville,
May 17-21, 2016. For further information about registration,
sponsorship or presentation opportunities contact Dr. Tate
(service@cyclodex.com).
About the Company: The CTD Holdings, Inc. Family of
Companies distributes and manufactures the trademarked Trappsol®
and Aquaplex® cyclodextrins, cyclodextrin derivatives, and
cyclodextrin complexes for research, nutrition, cosmetic and
medical markets. Sphingo Biotechnology, Inc. is developing
Trappsol® Cyclo™, an orphan drug designated product, for the
treatment of Niemann Pick Type C, a fatal genetic disease in young
children. NanoSonic Products, Inc. operates the world's only cGMP
pulse drying facility for the production of ultra-pure cyclodextrin
derivatives and pharmaceutical grade Aquaplex® cyclodextrin
complexes. CTD, Inc. supplies researchers around the globe from the
world's largest catalog of cyclodextrins. The companies offer a
wide variety of cyclodextrin related manufacturing services to
worldwide customers, including custom formulation, manufacturing,
and commercial scale supply of pharmaceutical grade cyclodextrin
complexes. For additional information, visit the Company's
websites: www.ctd-holdings.com and www.cyclodex.com
Safe Harbor Statement: This press release contains
"forward-looking statements" about the Company's current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
"anticipates," "believes" and "expects" or similar expressions, are
forward-looking statements. These statements are subject to a
number of risks, uncertainties and other factors that could cause
actual results in future periods to differ materially from what is
expressed in, or implied by, these statements. The factors which
may influence the Company's future performance include the
Company's ability to obtain additional capital to expand operations
as planned, success in attracting additional customers and
profitable contracts, and regulatory risks associated with
producing food and pharmaceutical grade products. These and other
risk factors are described from time to time in the Company's
filings with the Securities and Exchange Commission, including, but
not limited to, the Company's reports on Forms 10-K and 10-Q.
Unless required by law, the Company assumes no obligation to update
or revise any forward-looking statements as a result of new
information or future events.
Contact: Sitrick And Company Wendy Tanaka(415)
369-8447wtanaka@sitrick.com Thomas Mulligan(212) 573-6100, Ext.
395tmulligan@sitrick.com